Polio vaccines: time for a change in immunisation policy?
Beale
A J
AJ
Wellcome Biotech, Beckenham, UK.
D000914:Antibodies, Viral / Q000032:analysis; D002675:Child, Preschool; D003365:Costs and Cost Analysis; D003906:Developing Countries; D005069:Evaluation Studies as Topic; D006291:Health Policy; D006801:Humans; D007110:Immunity, Active; D007115:Immunization Schedule; D007223:Infant; D011051:Poliomyelitis / Q000209:etiology / Q000517:prevention & control*; D011055:Poliovirus Vaccine, Oral / Q000008:administration & dosage / Q000009:adverse effects / Q000145:classification / Q000276:immunology; D014611:Vaccination / Q000191:economics; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology
D000914:Antibodies, Viral; D011055:Poliovirus Vaccine, Oral; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated